This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Restenosis Following Paclitaxel Eluting Balloon Angioplasty of Hemodialysis Access Stenosis

This study has been completed.
Information provided by (Responsible Party):
University Health Network, Toronto Identifier:
First received: October 26, 2009
Last updated: November 14, 2014
Last verified: January 2012

Introduction: Narrowing of the draining vein occurs in >50% of hemodialysis fistula and left untreated will lead to loss of access. The narrowing is due to excessive growth of tissue in the vessel wall (intimal hyperplasia). The standard treatment is balloon dilatation. However, narrowing will inevitably recur in 2-3 months hence requiring further dilatation. Intimal hyperplasia also occurs in the heart and leg circulation. The drug paclitaxel has been used with great success in preventing intimal hyperplasia in these vessels following balloon dilatation. Administer locally, paclitaxel inhibits excess tissue growth in the vessel wall. The investigators believe that this drug will have similar effect in hemodialysis access..

Objective: To assess the effect of paclitaxel in hemodialysis access with narrowing. Paclitaxel is delivered by a paclitaxel-coated balloon. This balloon dilates the narrow segment and simultaneously delivers paclitaxel to the vessel wall.

Methodology: Patients with narrowed hemodialysis access are dilated with the paclitaxel-coated balloon or conventional balloon in randomized manner. The patency of the two groups are evaluated and compared at 6 months follow-up.

Potential benefit: Decrease number of balloon dilatations and hence hospital admissions, improve dialysis fistula function, and decrease overall economic cost.

Condition Intervention Phase
Renal Failure Device: Percutaneous Transluminal Angioplasty (PTA) Device: Paclitaxel Eluting Balloon Angioplasty Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Local Delivery of Paclitaxel for Prevention of Restenosis in Hemodialysis Access

Resource links provided by NLM:

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • Primary patency [ Time Frame: at 6 months ]

Secondary Outcome Measures:
  • Transonic blood flows [ Time Frame: monthly for up to 6 months ]

Enrollment: 32
Study Start Date: February 2012
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Conventional Balloon Angioplasty Device: Percutaneous Transluminal Angioplasty (PTA)
Angioplasty with the use of Conventional balloon
Experimental: Drug Eluting Balloon Angioplasty Device: Paclitaxel Eluting Balloon Angioplasty
Angioplasty with the use of paclitaxel eluting balloon
Other Name: Passeo-18 Lux (Biotronik)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hemodialysis access located in the forearm or upper arm
  • Patient with clinical or hemodynamic evidence of graft dysfunction
  • Hemodialysis access is > 3 months old

Exclusion Criteria:

  • Intervention of the vascular access circuit within the past 30 days
  • Thrombosed/clotted access
  • Evidence of systemic infection or a local infection associated with the graft
  • Positive pregnancy test within 7 days before enrolment
  • Patient is scheduled for a kidney transplant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01001676

Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2N2
Sponsors and Collaborators
University Health Network, Toronto
Principal Investigator: Kong Teng Tan, BCh MB University Health Network, Toronto
  More Information

Responsible Party: University Health Network, Toronto Identifier: NCT01001676     History of Changes
Other Study ID Numbers: ktt1
Study First Received: October 26, 2009
Last Updated: November 14, 2014

Keywords provided by University Health Network, Toronto:
renal failure
Dialysis access
Intimal hyperplasia

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017